Introduction
The Tumor Necrosis Factor (TNF)/TNF receptor superfamily is composed by more than 40 members, and controls a lot of genes essential for biological functions such as cellular differentiation, survival and death. Additionally TNF superfamily coordinates the development of numerous organs (Pfeffer 2003; Ware 2008) . Among this family, Osteoprotegerin (OPG or TNFRSF11B according the international nomenclature) is soluble glycoprotein that exists as both a 60kDa monomer and a 120 kDa disulfide-linked dimer.
OPG was originally characterized by two separate groups in 1997. Boyle and coworkers generated transgenic mice overexpressing various TNF receptor related cDNAs. A lineage of mice which over-expressed one specific cDNA developed a severe osteopetrosis due to a lack of osteoclasts. The protein encoded by this cDNA was therefore named osteoprotegerin, because it protected the bone from excessive resorption (Simonet et al. 1997) . The second group in Japan reported a factor which was able to inhibit osteoclastogenesis ). However, it was not until 1998 that both proteins were found to be equivalent.
Structurally, the mature form of OPG consists of 380 amino acids containing seven domains (Theoleyre et al. 2006; Baud'huin et al. 2007 ): four cysteine-rich N-terminal domains (domains 1-4), two death domain homologous regions (domains 5 and 6) and a Cterminal heparin-binding domain (domain 7). Domains 1-4 are structurally related to the TNF receptor family and are sufficient to abolish osteoclast differentiation and domains 5 and 6 can mediate a cytotoxic signal when they are included in a chimeric protein OPG-Fas ) but their physiological functions remain unclear. The last domain possesses a heparin binding domain. Similar heparin binding domains has been observed in the structure of many other proteins such as fibroblast growth factors and their receptors in which it plays numerous key functions (activation, autophosphorylation, etc) (Eswarakumar et al. 2005; Guerrini et al. 2007) . Additionally the presence of Cys-400 in the C-terminal portionwithin domain 7 is essential for OPG dimerization with the formation of disulfide bound ).
As OPG belongs to the TNF receptor family, it suggests that OPG has almost one ligand. The historical partner of OPG is RANKL which was identified few months following the description of OPG by the two same groups .
RANKL was initially discovered by two groups working on TNF-related cytokines thanks by its ability to sustain dendritic cell survival (Anderson et al. 1997; Wong et al. 1997) . OPG is therefore a decoy receptor for the pro-osteoclastic cytokine RANKL (Theoleyre et al. 2004; Baud'huin et al. 2007 ) with a high affinity equivalent to RANKL for its receptor RANK (TNFRSF11A) ( Table 1 ). The binding of OPG to RANKL prevents the interaction of RANKL for RANK expressed on the cell surface of osteoclast precursors, and thus inhibits the formation of osteoclasts (Boyle et al. 2003) . Since then, numerous ligands for OPG have been identified: TRAIL (Emery et al. 1998) , syndecan-1 (Standal et al. 2002) , glycosaminoglycans (GAGs) (Theoleyre et al. 2006; Lamoureux et al. 2009 ), von Willebrand Factor (Zannettino et al. 2005) and Factor VIII-von Willebrand Factor complex (Table 1 ). This review focuses on the multiple biological functions achieved by OPG through the binding to its various ligands.
RANKL and TRAIL: ligands from the TNF family
RANKL is a transmembrane glycoprotein expressed on the surface of osteoblasts, stromal cells and T cells, however this molecule can be cleaved by proteases to give soluble RANKL with the same biological activity. The proteolytic cleavage is carried out by matrix metalloproteases or ADAMs (Georges et al. 2009 ). In bone, RANKL binds to its specific receptor RANK which is expressed on the membrane of osteoclast progenitors.
Stoichiometrically, RANKL forms an homotrimeric protein and interacts with three monomers of RANK linked by disulfide bounds (Theoleyre et al. 2006) . The binding of RANK to RANKL leads to the activation of several pathways involved in the differentiation, activation and survival of osteoclast. The RANK/RANKL is thus mandatory for the formation of mature osteoclasts. It has been shown that mice lacking Rankl did not have osteoclasts and suffered from severe osteopetrosis (Kong et al. 1999 ).
The osteoclastogenesis is a tightly regulated process with the modulation of RANK/RANKL signaling by OPG which acts as a decoy receptor for RANKL. In bone, OPG is secreted by stromal cells and other cell types including osteoblastic lineage cells. The evidence showing the importance of OPG in bone biology was provided by studies based on genetic experiments. OPG-overexpressing mice exhibit severe osteopetrosis and a reduced number of mature osteoclasts (Simonet et al. 1997) on the other hand OPG-knockout mice are osteoporotic with a decreased bone density and a high incidence of fractures and bone deformities (Bucay et al. 1998; Mizuno et al. 1998) . The interaction between RANKL and OPG consists of two anchoring points on OPG for RANKL by amino acids 68, 69, 82, and amino acids 88-91, 111, and 116-120 (Figure 1 ) ). However, it has been shown that the homodimeric form of OPG exhibits a much greater higher affinity for the homotrimeric form of RANKL (Schneeweis et al. 2005; Theoleyre et al. 2006 ). More recently, the crystal structure of the interaction between RANKL and OPG was described (Luan et al. 2012) . In this study, the authors showed that OPG (Domains 1 to 4) is able to interact with RANKL in a 1:1 ratio, and blocks the accessibilities of important biding sites of RANKL to RANK. This competitive interaction within the triad RANK/RANKL/OPG suggests that OPG can have also an effect in tissues other than bone where RANKL is active. In this context, the RANKL-RANK system influences processes in the immune system. Both RANK -/-and RANKL -/-mice have a defect in the maturation of T and B cells suggesting by the phenotype of implicating these molecules in lymphocyte and lymph node development (Dougall et al. 1999; Kong et al. 1999) . From this perspective, Yun and coworkers showed that OPG regulates B cell maturation and development; population of B cells was indeed increased in OPG-null mice. Moreover, the dendritic cells generated from these mice have an increased ability to stimulate T cells (Yun et al. 2001 ). This study suggests that OPG has a pivotal role in the immune response and can mediate cell survival.
This latter function is reinforced by the fact that OPG is able to bind to TNF-related apoptosis inducing ligand (TRAIL) and thus block TRAIL-induced apoptosis of Jurkat cells (Emery et al. 1998) . TRAIL is a member of the TNF superfamily produced by immune cells within the tumor environment. TRAIL binds to its receptors as a homotrimer form, this trimeric form being biologically much more active than the monomeric one (Wiley et al. 1995) . There are five TRAIL receptors described so far; two of these receptors (DR4 and DR5) contain death domain motifs and promote apoptosis. On the other hand, DcR1, DcR2
and OPG are unable to induce apoptosis and function as decoy receptors. OPG is binding to TRAIL with a comparable affinity to that of RANKL (Table 1 ) and the binding sites involve on OPG residues ( Figure 1 ). The direct biological consequence of the interaction of OPG with TRAIL is the inhibition of TRAIL-induced apoptosis in numerous cancer cells (Holen et al. 2002; Shipman et al. 2003; Neville-Webbe et al. 2004 ). This mechanism could be important in the release from cell death, as suggested by the production of OPG by tumor cells (Holen et al. 2002; Heymann 2012 ).
Additional studies have been performed using bone marrow stromal cells (BMSCs) derived from either breast or prostate cancer patients. In both cancer types, BMSCs were found to produce sufficient levels of OPG to protect tumor cells from TRAIL-induced apoptosis. This suggests that bone-derived OPG may be involved in promoting survival of these tumor cell types within the bone microenvironment (Neville-Webbe et al. 2004; Nyambo et al. 2004) . In this context, a peptide-mimetic of OPG (OP3-4) was developed to treat bone disease in multiple myeloma and keep the TRAIL activity. OP3-4 was able to inhibit osteoclastogenesis of murine blood mononuclear cells but did not inhibit TRAILinduced apoptosis of multiple myeloma cells (Heath et al. 2007 ). Moreover, recent in vivo experiment showed that anticancer efficacy of recombinant soluble Apo2L/TRAIL is retained in the bone microenvironment where biologically active OPG may be present at high concentrations (Zinonos et al. 2011) . Taken together, OPG may have a dual function in tumor, promoting cancer cell survival through its binding to TRAIL and on the other hand limiting the tumor growth in cancer induced bone disease due to the inhibition of RANKL.
Thus, in a model of osteosarcoma, OPG administered by gene transfer reduced tumor incidence and local tumor growth ). The mechanism suggested mentioned that OPG exerts indirect inhibitory effect on tumor progression through the inhibition of RANKL whose production is enhanced in bone tumor environment.
The ability of OPG to bind both to RANKL and TRAIL gives to him the potency to regulate bone biology and tumor biology through direct effect on osteoclasts or cancer cells.
However, in vascular biology, these three partners play a pivotal role which has numerous outcomes in the physiopathology of vascular system. OPG is largely expressed in the vascular tissues including the heart, arteries and veins, and is constitutively secreted by endothelial cells and vascular smooth muscle cells (Chikatsu et al. 2002; Collin-Osdoby 2004; Chollet et al. 2010) . In oncologic context, endothelial cells closely located to tumor cells strongly express OPG, especially in metastatic foci . The presence of arterial calcification of the media of the aorta and the renal arteries in OPG-deficient mice suggest the involvement of OPG in vascular biology (Bucay et al. 1998) . In accordance with these data,
Price and co-workers showed that administration of exogenous OPG prevent vascular calcification induced by warfarin or high vitamin D doses (Price et al. 2001) . Paradoxically, clinical studies suggest that high serum OPG levels correlate with the severity of vascular calcification, coronary artery disease and heart failure. (Ueland et al. 2005; Ziegler et al. 2005; Helske et al. 2007 ). Very recently, it has been shown that OPG is more frequently expressed in atheromatous carotid plaques than femoral specimens, and correlates with the abundance of macrophages in the lesions . These clinical findings are controversial with in vitro data. Indeed the inhibitory effect of OPG on vascular calcification in animal models could be passive or cellular. As mentioned above, OPG exerts an antiapoptotic effect towards TRAIL and decreases in consequence the number of apoptotic bodies that may serve as nucleation sites for passive mineralization (Fleishman et al. 1990; Benslimane-Ahmim et al. 2011) . Several studies have shown also that recombinant OPG can promote the survival/proliferation of mature vascular endothelial cells (Malyankar et al. 2000; Pritzker et al. 2004; Cross et al. 2006; Kobayashi-Sakamoto et al. 2006; McGonigle et al. 2009 ). Similarly, Lawrie et al showed OPG promotes the proliferation and the migration of pulmonary artery smooth muscle cell, and thus evidenced an important role of OPG in the pathogenesis of pulmonary arterial hypertension (Lawrie et al. 2008) . However, the precise mechanism remains unclear and seems to involve multipartners. One study although suggests that OPG is blocking the apoptosis induced by TRAIL (Pritzker et al. 2004) . It has been clearly demonstrated that OPG is able to stimulate endothelial colony-forming cells and thus The full length OPG binds to a wide variety of GAGs through its heparin binding domain in contrast to OPG-Fc in which the heparin-binding domain is lacking (Theoleyre et al. 2006; Lamoureux et al. 2009 ). The capacity of GAGs to bind to OPG can be evaluated by BIAcore analysis (Figure 2 ). Among the different GAGs, heparin presents the highest affinity for OPG (Kd: 1.3.10 -10 M for heparin, see Table 1 ).The dissociation constant is higher (hundred fold) for dermatan sulfate (DS) and chondroitin sulfate (CS) (3.7.10 -8 and 2.10 -8 M respectively, Table1). This lower affinity is mainly due to the degree of sulfation as recently confirmed by Robinson et al. and by Salbach et al. (Robinson et al. 2012; Salbach et al. 2012 ). Heparin, indeed, is the most sulfated GAGs compared to CS and DS (Velasco et al. 2010 ). Moreover, a highly sulfated exopoly-saccharide derived from Altermonasinfernus ) has a binding affinity comparable to heparin (2.10 -10 M, Table 1 ). The length of GAGs is another property of GAGs that govern their binding to OPG. As shown in Figure 2 and Table 1 , oligosaccharide made of 4 sugar units (dp4) is much less affine for OPG than an oligosaccharide made of 18 sugar units (dp18) (Kd of 7.10 -7 and 2.8.10 -8 M respectively). As represented in Figure 2F , heparin is able to shift the binding of OPG to heparin immobilized on the sensorchip. The other GAGs studied are also able to shift the binding but a concentration 100 fold greater is required. This competition binding confirmed the importance of sulfation and size of GAGs for their biological activities. Thus, we have recently showed that GAGs act directly on osteoclastogenesis (Baud'huin et al. 2011). We found that heparin and others GAGs are able to inhibit the differentiation of osteoclast precursors into osteoclasts through an inhibition of cell adhesion. Our study confirmed also that the length and the sulfation are critical parameters in the inhibition of osteoclastogenesis.
On the contrary, Irie and co-workers (Irie et al. 2007) showed that GAGs by binding to OPG prevent OPG-mediated inhibition of osteoclastic differentiation, and therefore enhance bone resorption. Furthermore, Lamoureux et al. showed that GAGs inhibit full length OPG binding to TRAIL or to RANKL but not OPG truncated form lacking its heparin binding domain (Lamoureux et al. 2009 ). Thus, GAGs may represent potent regulators of OPG availability and anti-tumor activity in bone tumor microenvironment (Lamoureux et al. 2008 ).
The binding of OPG with GAGs implies also activities through interaction with PGs.
The first role of the OPG heparin-binding domain has been revealed by Standal (Standal et al. 2002) who demonstrated that myeloma cells internalize and degrade OPG through its binding to syndecan-1 and consequently increase the local RANKL concentration andso induce osteolysis in patients. Moreover, OPG induces osteopontin expression via syndecan-1 and activates phosphoinositol 3-kinase/Akt in human periodontal ligament cells (Yongchaitrakul et al. 2009 ). PGs are also involved in OPG-induced chemotaxis of monocytes (Mosheimer et al. 2005) . Indeed, OPG can interact with syndecan-1 expressed by monocytes (potential osteoclast precursors) and can stimulate the cell migration. In this context, OPG is a chemotactic factor for monocytes which can be recruited in inflammatory context or during osteolysis process.OPG seems also to modulate cell adhesion. Indeed, OPG stimulates the expression of the cell adhesion molecule angiopoietin-2 in TNF-activated cells (Mangan et al. 2007) , increases leucocyte adhesion to endothelial cells (Zauli et al. 2007 ) and stimulates proliferation and migration of human microvascular endothelial cells (Kobayashi-Sakamoto et al. 2008) . Proteoglycans and GAGs have been suspected to initiate these OPG activities.
Taken together, these data show that PGs and GAGs are key partners for biological activities of OPG (inhibition of osteoclastogenesis in vitro, bioavailability of OPG and monocyte chemotaxis in favour of pro-osteolytic activity). In this context, we investigate the role of OPG on human monocytes adhesion and its control by GAGs. After 5 days of culture, human CD14 + cells cultured in the presence of human OPG (100 ng/mL) strongly adhere to the plastic, whereas very few cells adhere in culture medium alone (0.3% of the initial monocytes number) (Figure3A). This is confirmed by the cell counting, OPG increased by 25
fold the number of adherent monocytes ( Figure 3B ). When 125 µg/mL of heparin was added to the OPG-containing culture medium, the effect of OPG on CD14 + cell adhesion was completely abolished ( Figure 3A , p < 0.001). The sulfation and the size of the GAGs chains are involved in this inhibition of OPG-mediated adhesion. Thud, DS and dp18 added to the culture are able to inhibit OPG effect with the same intensity as heparin (99% of inhibition, Figure 3C ). On the contrary, the OPG-induced CD14 + cell adhesion was inhibited by 50%in the presence of dp4 and chondroitin sulfate ( Figure 3C ).We then investigated the signaling pathway involved in the adhesion of CD14 + cells induced by OPG. We found that OPG is able to activate the PI3k / Akt pathway. As shown in Figure 2D , OPG induces phosphorylation of Akt after 10 minutes which is maintained at 45 minutes. The induction of phosphorylation was inhibited by heparin. Our data suggest that OPG could promote monocyte adhesion through an Akt/PI3-Kinase signaling pathway and recruit monocytes where OPG is produced (bone, endothelial cells). However, this phenomenon is a long process during around 5 days, compare to the ability of OPG to induce leucocyte adhesion to endothelial cells in 5 to 15 minutes (Zauli et al. 2007 ). This data suggests that OPG facilitates the recruitment of monocytes where OPG is produced, such as bone microenvironment, vasculature and tumor context. shown that OPG is also colocalised with vWF in alpha granules of platelets and megakaryocytes (Chollet et al. 2010) . OPG interacts with the A1 domain of vWF and remains associated after secretion from endothelial cells (Shahbazi et al. 2007 ). The binding site of OPG to vWF has common domain with the binding site of GP1Ba protein to vWF which facilitates initial platelet adhesion (Figure 4 ). The binding affinity of vWF for OPG (3,5.10 -9 M) is comparable with that of OPG for RANKL as mentioned in Table 1 . Taken together, these data support a possible role of vWF-OPG complex in regulation of endothelial cells survival, osteoclast differentiation, vascular injury and inflammation such as thrombus formation (Zannettino et al. 2005; Lenting et al. 2010 ).
The complex FVIII/vWF is also able to bind to OPG (Kd = 7,2.10 -8 M, Table 1 showed that the synovium in hemophilic arthropathy highly expressed RANK and RANKL in contrast to OPG which decreased suggesting an activation of the resorptive process. They concluded that low tissue expression of OPG paralleled its serum levels and the severity of hemophilic arthropathy (Melchiorre et al., 2012) . .These data are consistent with a randomized study showing that the prophylaxis with recombinant Factor VIII prevents joint damages in young haemophilic patients (Manco-Johnson et al. 2007 ), possibly through a decrease in osteoclastogenesis.
Conclusions
OPG has mainly been described as an anti-resorptive cytokine, as the first ligand reported was RANKL. However since that time, numerous ligands were described and studied in the last fifteen years giving to OPG an important role in vascular, tumor and immune biology ( Figure   5 ). Clinical outcomes confirm that OPG is an active cytokine in a wide range of pathologies (osteoporosis, arthritis, vascular calcification, cancer bone-related disease) and can be considered as a biological marker or/and therapeutic targets for these pathologies. But the mechanisms by which OPG and its multiple partners act together and/or sequentially remain uncertain and need further investigation.
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